Amy Vandenberg - Net Worth and Insider Trading

Amy Vandenberg Net Worth

The estimated net worth of Amy Vandenberg is at least $11,959 dollars as of 2024-11-13. Amy Vandenberg is the Chief Clinical & Reg Officer of Obalon Therapeutics Inc and owns about 3,921 shares of Obalon Therapeutics Inc (OBLN) stock worth over $11,959. Details can be seen in Amy Vandenberg's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Amy Vandenberg has not made any transactions after 2019-08-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Amy Vandenberg

To

Amy Vandenberg Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Amy Vandenberg owns 2 companies in total, including Obalon Therapeutics Inc (OBLN) , and Reshape Lifesciences Inc (RSLS) .

Click here to see the complete history of Amy Vandenberg’s form 4 insider trades.

Insider Ownership Summary of Amy Vandenberg

Ticker Comapny Transaction Date Type of Owner
OBLN Obalon Therapeutics Inc 2020-01-24 Chief Clinical & Reg Officer
RSLS Reshape Lifesciences Inc 2016-10-05 VP of Reg. and Clin. Affairs

Amy Vandenberg Latest Holdings Summary

Amy Vandenberg currently owns a total of 1 stock. Amy Vandenberg owns 3,921 shares of Obalon Therapeutics Inc (OBLN) as of August 6, 2019, with a value of $11,959.

Latest Holdings of Amy Vandenberg

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
OBLN Obalon Therapeutics Inc 2019-08-06 3,921 3.05 11,959

Holding Weightings of Amy Vandenberg


Amy Vandenberg Form 4 Trading Tracker

According to the SEC Form 4 filings, Amy Vandenberg has made a total of 0 transactions in Obalon Therapeutics Inc (OBLN) over the past 5 years. The most-recent trade in Obalon Therapeutics Inc is the acquisition of 833 shares on August 6, 2019, which cost Amy Vandenberg around $10,000.

Insider Trading History of Amy Vandenberg

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Amy Vandenberg Trading Performance

GuruFocus tracks the stock performance after each of Amy Vandenberg's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Amy Vandenberg is -43.38%. GuruFocus also compares Amy Vandenberg's trading performance to market benchmark return within the same time period. The performance of stocks bought by Amy Vandenberg within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Amy Vandenberg's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Amy Vandenberg

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -43.38 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -46.74 LIMIT LIMIT LIMIT LIMIT LIMIT

Amy Vandenberg Ownership Network

Ownership Network List of Amy Vandenberg

No Data

Ownership Network Relation of Amy Vandenberg

Insider Network Chart

Amy Vandenberg Owned Company Details

What does Obalon Therapeutics Inc do?

Who are the key executives at Obalon Therapeutics Inc?

Amy Vandenberg is the Chief Clinical & Reg Officer of Obalon Therapeutics Inc. Other key executives at Obalon Therapeutics Inc include director & President & CEO & Exec Chairman Andrew P Rasdal , Chief Financial Officer Nooshin Hussainy , and Chief Technology Officer Mark Brister .

Obalon Therapeutics Inc (OBLN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Obalon Therapeutics Inc (OBLN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Obalon Therapeutics Inc (OBLN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Obalon Therapeutics Inc (OBLN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Obalon Therapeutics Inc Insider Transactions

No Available Data

Amy Vandenberg Mailing Address

Above is the net worth, insider trading, and ownership report for Amy Vandenberg. You might contact Amy Vandenberg via mailing address: C/o Obalon Therapeutics, Inc., 5421 Avenida Encinas, Suite F, Carlsbad Ca 92008.